MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

MDT

85.26

-0.95%↓

A

120.85

-0.66%↓

VEEV

168.97

+0.64%↑

HQY

86.11

+0.21%↑

NEOG

9.63

+1.37%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Search

Voyager Therapeutics Inc

Closed

4.22 2.43

Overview

Share price change

24h

Current

Min

4.07

Max

4.33

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+255.21% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	345K 229M
Previous open	1.79
Previous close	4.22

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 kwi 2026, 23:49 UTC

Major News Events

New Zealand 1Q Inflation Higher Than Expected

20 kwi 2026, 23:10 UTC

Hot Stocks

Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT

20 kwi 2026, 22:53 UTC

Major Market Movers

BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment

20 kwi 2026, 23:45 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

20 kwi 2026, 23:44 UTC

Market Talk

Gold Consolidates as End of Cease-Fire Looms -- Market Talk

20 kwi 2026, 23:39 UTC

Market Talk

Rio Tinto Posts Strong Start to Year -- Market Talk

20 kwi 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 kwi 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

20 kwi 2026, 23:30 UTC

Market Talk

Super Retail's Earnings Outlook Less Rosy -- Market Talk

20 kwi 2026, 23:09 UTC

Market Talk

Viva Energy's Refinery Fire More Benign Than Jefferies Thought -- Market Talk

20 kwi 2026, 22:31 UTC

Acquisitions, Mergers, Takeovers

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 kwi 2026, 22:26 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says Sanbrado, Toega Operations Not Subject to Govt Request for Additional Participation

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Plans to Distribute Cash Proceeds to Shareholders Via Special Dividend

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Aims for Acquisition to Be Completed by End-2026

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says to Work Cooperatively With Govt to Finalize Deal Terms

20 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says Acquisition Would Be for A$175 Million

20 kwi 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

West African Resources Says Burkina Faso Govt Issues Decree to Acquire 25% of Kiaka

20 kwi 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Anthropic, Amazon Tighten Bond in $5 Billion Investment and Computing Deal -- WSJ

20 kwi 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Amazon Invests $5B in Anthropic Amid Expanded Collaboration

20 kwi 2026, 21:38 UTC

Market Talk

Apple's New CEO Will Face Immediate Pressure on AI Strategy -- Market Talk

20 kwi 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Uber Expands Stake In Lucid for Robo-Taxis. This Is How Tesla's Stock Is Responding. -- Barrons.com

20 kwi 2026, 21:24 UTC

Market Talk

Apple's CEO Change Timing Will Garner Mixed Reaction, Analyst Says -- Market Talk

20 kwi 2026, 21:24 UTC

Market Talk

Global Equities Roundup: Market Talk

20 kwi 2026, 21:13 UTC

Earnings

Alaska Air: Expansion of Card Portfolio Expected to Accelerate Loyalty Platform Beyond Incremental $150M Profit Outlined in Alaska Accelerate Strategy

20 kwi 2026, 21:10 UTC

Earnings

Alaska Air to Move Toward a Single Issuer for Atmos Rewards Credit Cards

20 kwi 2026, 21:09 UTC

Earnings

Alaska Air Sees 2Q Capacity Up About 1% Year-Over-Year, Down Nearly a Point From Original Views, on 'Proactive Trimming' of May and June Capacity

20 kwi 2026, 21:08 UTC

Earnings

Alaska Air 'Continues to Operate From a Position of Strength,' With Healthy Balance Sheet, Strong Liquidity, About $20B in Unencumbered Assets

20 kwi 2026, 21:07 UTC

Earnings

Alaska Air: Taken Together, Rev, Cost and Fuel Assumptions Result in 2Q Adjusted Loss Per Share Estimate of About $1

20 kwi 2026, 21:05 UTC

Earnings

Alaska Air: This Assumption Adds About $600M of Expense to 2Q, Equivalent to EPS Headwind of $3.60

20 kwi 2026, 21:05 UTC

Earnings

Alaska Air Expects 2Q Fuel Cost to Average About $4.50 Based on Forward Curve Today

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

255.21% upside

12 Months Forecast

Average 14.67 USD 255.21%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

8

Buy

0

Hold

0

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Other stocks from the sector

MDT

Medtronic PLC

85.26

A

Agilent Technologies Inc

120.85

VEEV

Veeva Systems Inc

168.97

HQY

HealthEquity Inc

86.11

NEOG

Neogen Corp

9.63

Live chat